Company / Operating Cash Flow per Share
Halozyme Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
$5.29
FY2025
5-year range
-$0.63 / $5.29
FY2021-FY2025
Trend
+40.0%
vs FY2024
Sector context
#22 of 212
Health Care
What the data says
Among 212 Health Care companies, Halozyme is in the top 10% for operating cash flow per share. Operating Cash Flow per Share has increased for 4 consecutive years, from $-0.63 in FY2021 to $5.29 in FY2025.
Based on SEC 10-K filings.
5.29 in FY2025 with a 3-year CAGR of +44.7%. Top quartile in the Health Care sector.
Improved from $2.88 to $5.29 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- +44.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
In line with sector average
Key checks
Key Insights
- Halozyme's operating cash flow per share has grown for 4 consecutive years.
- In FY2025, operating cash flow per share increased 40.0% year-over-year.
- Ranks #22 out of 212 companies in the Health Care sector.
- Lowest operating cash flow per share in the period was in FY2021.
Company context
Key Data Points
- Strong profit margin: 47.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 118.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.29 | +40.0% |
| FY2024 | $3.78 | +31.4% |
| FY2023 | $2.88 | +64.6% |
| FY2022 | $1.75 | +376.0% |
| FY2021 | -$0.63 | -74.7% |
| FY2020 | -$0.36 | -139.1% |
| FY2019 | $0.93 | +367.2% |
| FY2018 | -$0.35 | -133.5% |
| FY2017 | $1.04 | +379.2% |
| FY2016 | -$0.37 | +5.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026